608 not checked

3SBio · 608 dose

FollowEvery change as it happens, and a Monday email
Next date
Phase 3 trial completes
Trials
3 active
4 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Ankylosing Spondylitis, Axial Spondyloarthritis, Non-Radiographic, Axial Spondyloarthritis
Main trialPhase 3
“This study will evaluate the efficacy and safety of 608 in patients with AS.”In the company’s words, NCT07261644 on ClinicalTrials.gov
Other names
608 dose

Other drugs for Ankylosing Spondylitis

All 9 drugs for Ankylosing Spondylitis

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 14 Jan 2027 A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS)
Phase 3Not yet recruiting 19 Apr 2028 A Study to Evaluate the Efficacy and Safty of 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)
Phase 2Recruiting 22 Sep 2025 A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)
Phase 2Unknown May 2023 A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow 608

Following is part of Solo: you see every change to 608 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in